Shots:
- The P-III HIMALAYA study Imfinzi monothx. and the STRIDE regimen (single priming dose of tremelimumab 300mg + Imfinzi 1500mg followed by Imfinzi q4w vs sorafenib in ~1,324 patients with unresectable, advanced HCC who had not been treated with prior systemic therapy and were not eligible for locoregional therapy
- The combination regimen demonstrated a favorable safety profile & the addition of tremelimumab to Imfinzi did not increase severe hepatic toxicity. Imfinzi monothx. demonstrated a non-inferior OS to sorafenib
- Imfinzi and tremelimumab received the US FDA’s ODD for the treatment of HCC in 2020 whereas Tremelimumab was granted ODD in the EU in HCC in 2020
Click here to read the full press release/ article | Ref: AstraZeneca | Image: Twitter
The post AstraZeneca Reports Results of Imfinzi + Tremelimumab in P-III HIMALAYA Study for 1L Treatment of Unresectable Liver Cancer first appeared on PharmaShots.
